Fig. 01 -

Title Slide

Fig. 02 -

Disclosure

Fig. 03 -

Objectives

Fig. 04 -

Vasculopathy

Fig. 05 -

Where to start?

Fig. 06 -

Hemodynamic Definition

Fig. 07 -

World Symposium

Fig. 08 -

Hemodynamic Definition

Fig. 09 -

HD of PH

Fig. 10 -

WHO Classification

Fig. 11 -

WHO Groups

Fig. 12 -

WHO Group I

Fig. 13 -

WHO Group 2

Fig. 14 -

WHO Group 3

Fig. 15 -

WHO Group 4

Fig. 16 -

CTEPH vs SVD

Fig. 17 -

WHO Group 5

Fig. 18 -

Clinical Evaluation

Fig. 19 -

CE Flow Chart

Fig. 20 -

Functional Assessment

Fig. 21 -

Normal Heart

Fig. 22 -

Echo

Fig. 23 -

Echo: Table 1

Fig. 24 -

TAPSE

Fig. 25 -

Risk and Prognosis

Fig. 26 -

Registries Assessing Risk

Fig. 27 -

ESC/ERS

Fig. 28 -

Survival in PAH

Fig. 29 -

Risk Calculators

Fig. 30 -

REVEAL and Prognosis

Fig. 31 -

Reveal Lite 2

Fig. 32 -

French Non-invasive

Fig. 33 -

Suggested Assessment

Fig. 34 -

Treatment

Fig. 35 -

Treatment Pathways

Fig. 36 -

Nitric Oxide Pathway

Fig. 37 -

Endothelin Pathway

Fig. 38 -

Prostacyclin Pathway

Fig. 39 -

IV/SC Therapy

Fig. 40 -

Risk Stratification Treatment

Fig. 41 -

Acute Vasoreactivity Test

Fig. 42 -

Vasoactive Challenge

Fig. 43 -

Risk Combinations

Fig. 44 -

Seraphin Trial

Fig. 45 -

Riociguat

Fig. 46 -

Soluble Guanylate

Fig. 47 -

Up-Front

Fig. 48 -

GRIPHON Trial

Fig. 49 -

Lung Transplantation

Fig. 50 -

Transplant

Fig. 51 -

Case

Fig. 52 -

Case: Female

Fig. 53 -

Exam and Results

Fig. 54 -

Echo and Cath

Fig. 55 -

Risk Calculator

Fig. 56 -

Guidelines & French Criteria

Fig. 57 -

Follow up…

Fig. 58 -

Good Enough?

Fig. 59 -

Initial Treatment Approach

Fig. 60 -

Initial Treatment Strategy

Fig. 61 -

Compera 2.0

Fig. 62 -

Strata Models

Fig. 63 -

Risk at Baseline

Fig. 64 -

Recent Updates

Fig. 65 -

Emerging Therapies

Fig. 66 -

PAH and Sotatercept

Fig. 67 -

Inhaled Tyvaso

Fig. 68 -

Interstitial Lung Disease

Fig. 69 -

Unexpected Improvement

Fig. 70 -

Inhaled Therapy

Fig. 71 -

Summary

Fig. 72 -

Thank You